• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

依赖于 Epstein-Barr 病毒启动子 Wp 的潜伏期间蛋白质表达的反式抑制。

trans-Repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency.

机构信息

Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033, USA.

出版信息

J Virol. 2011 Nov;85(21):11435-47. doi: 10.1128/JVI.05158-11. Epub 2011 Aug 24.

DOI:10.1128/JVI.05158-11
PMID:21865378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3194970/
Abstract

An ordered silencing of Epstein-Barr virus (EBV) latency gene transcription is critical for establishment of persistent infection within B lymphocytes, yet the mechanisms responsible and the role that the virus itself may play are unclear. Here we describe two B-cell superinfection models with which to address these problems. In the first, Burkitt lymphoma (BL) cells that maintain latency I, when superinfected, initially supported transcription from the common EBNA promoters Wp and Cp (latency III) but ultimately transitioned to latency I (Cp/Wp silent), an essential requirement for establishment of EBV latency in vivo. We used this model to test whether the early lytic-cycle gene BHLF1, implicated in silencing of the Cp/Wp locus, is required to establish latency I. Upon superinfection with EBV deleted for the BHLF1 locus, however, we have demonstrated that BHLF1 is not essential for this aspect of EBV latency. In the second model, BL cells that maintain Wp-restricted latency, a variant program in which Cp is silent but Wp remains active, sustained the latency III program of transcription from the superinfecting-virus genomes, failing to transition to latency I. Importantly, there was substantial reduction in Wp-mediated protein expression from endogenous EBV genomes, in the absence of Cp reactivation, that could occur independent of a parallel decrease in mRNA. Thus, our data provide evidence of a novel, potentially posttranscriptional mechanism for trans-repression of Wp-dependent gene expression. We suggest that this may ensure against overexpression of the EBV nuclear antigens (EBNAs) prior to the transcriptional repression of Wp in cis that occurs upon activation of Cp.

摘要

埃泼斯坦-巴尔病毒 (EBV) 潜伏期基因转录的有序沉默对于 B 淋巴细胞中持续性感染的建立至关重要,但负责这些机制的机制以及病毒本身可能发挥的作用尚不清楚。在这里,我们描述了两种可以解决这些问题的 B 细胞超感染模型。在第一个模型中,维持潜伏期 I 的伯基特淋巴瘤 (BL) 细胞在被超感染时最初支持从共同的 EBNA 启动子 Wp 和 Cp(潜伏 III)转录,但最终过渡到潜伏期 I(Cp/Wp 沉默),这是 EBV 在体内建立潜伏所必需的。我们使用该模型来测试早期裂解周期基因 BHLF1 是否需要建立潜伏 I,该基因被认为参与 Cp/Wp 基因座的沉默。然而,在 EBV 缺失 BHLF1 基因座的超感染后,我们已经证明 BHLF1 对于 EBV 潜伏的这一方面不是必需的。在第二个模型中,维持 Wp 限制潜伏的 BL 细胞,这是一种沉默 Cp 但 Wp 保持活跃的变体程序,维持了来自超感染病毒基因组的潜伏 III 转录程序,未能过渡到潜伏 I。重要的是,在没有 Cp 重新激活的情况下,从内源性 EBV 基因组中 Wp 介导的蛋白质表达会大幅减少,这可能独立于 mRNA 的平行减少而发生。因此,我们的数据提供了证据,证明了一种新的、潜在的转录后机制,用于反式抑制 Wp 依赖性基因表达。我们认为,这可以确保在 Cp 激活时发生顺式 Wp 转录抑制之前,不会过度表达 EBV 核抗原 (EBNAs)。

相似文献

1
trans-Repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency.依赖于 Epstein-Barr 病毒启动子 Wp 的潜伏期间蛋白质表达的反式抑制。
J Virol. 2011 Nov;85(21):11435-47. doi: 10.1128/JVI.05158-11. Epub 2011 Aug 24.
2
The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.EB 病毒 BHLF1 基因座促进病毒潜伏期和 B 细胞永生化。
J Virol. 2020 Aug 17;94(17). doi: 10.1128/JVI.01215-20.
3
Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.在B细胞感染的初始阶段,爱泼斯坦-巴尔病毒核抗原1(EBNA1)基因的转录发生在BCR2(Cp)EBNA基因启动子诱导之前。
J Virol. 1996 Jun;70(6):3561-70. doi: 10.1128/JVI.70.6.3561-3570.1996.
4
Methylation of the EBV genome and establishment of restricted latency in low-passage EBV-infected 293 epithelial cells.EBV基因组的甲基化以及低传代EBV感染的293上皮细胞中受限潜伏期的建立。
Virology. 2002 Jul 20;299(1):109-21. doi: 10.1006/viro.2002.1457.
5
The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.爱泼斯坦-巴尔病毒BamHI C启动子对于体外B细胞永生化并非必需,但它能极大地增强B细胞生长转化。
J Virol. 2015 Mar;89(5):2483-93. doi: 10.1128/JVI.03300-14. Epub 2014 Dec 24.
6
The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.爱泼斯坦-巴尔病毒(EBV)核抗原1 BamHI F启动子在EBV转化的B细胞进入裂解周期时被激活。
J Virol. 1992 Dec;66(12):7461-8. doi: 10.1128/JVI.66.12.7461-7468.1992.
7
EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.EBNA2 缺失型 Epstein-Barr 病毒(EBV)分离株 P3HR1 可在人源化小鼠中引起霍奇金样淋巴瘤和弥漫性大 B 细胞淋巴瘤,并具有 II 型和 Wp 局限型潜伏期类型。
PLoS Pathog. 2020 Jun 15;16(6):e1008590. doi: 10.1371/journal.ppat.1008590. eCollection 2020 Jun.
8
Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.地方性 Burkitt 淋巴瘤(BL)中 Epstein-Barr 病毒潜伏的不同模式导致 BL 相关基因表达特征内的不同变体。
J Virol. 2013 Mar;87(5):2882-94. doi: 10.1128/JVI.03003-12. Epub 2012 Dec 26.
9
Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.通过抑制前体mRNA加工对爱泼斯坦-巴尔病毒核抗原1表达的自我抑制
J Virol. 2008 Feb;82(4):1679-87. doi: 10.1128/JVI.02142-07. Epub 2007 Dec 12.
10
oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.oriP对于爱泼斯坦-巴尔病毒永生化淋巴母细胞系中EBNA基因启动子活性至关重要。
J Virol. 1996 Sep;70(9):5758-68. doi: 10.1128/JVI.70.9.5758-5768.1996.

引用本文的文献

1
Studies and Clinical Observations Imply a Synergistic Effect Between Epstein-Barr Virus and Dengue Virus Infection.研究与临床观察表明,爱泼斯坦-巴尔病毒与登革病毒感染之间存在协同效应。
Front Microbiol. 2021 Jun 18;12:691008. doi: 10.3389/fmicb.2021.691008. eCollection 2021.
2
Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.组蛋白加载器 CAF1 和 HIRA 限制 EBV B 细胞裂解激活。
mBio. 2020 Oct 27;11(5):e01063-20. doi: 10.1128/mBio.01063-20.
3
The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.EB 病毒 BHLF1 基因座促进病毒潜伏期和 B 细胞永生化。
J Virol. 2020 Aug 17;94(17). doi: 10.1128/JVI.01215-20.
4
Comparative Analysis of Gammaherpesvirus Circular RNA Repertoires: Conserved and Unique Viral Circular RNAs.γ疱疹病毒环状 RNA 谱的比较分析:保守和独特的病毒环状 RNA。
J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.01952-18. Print 2019 Mar 15.
5
The Epstein Barr virus circRNAome.EB 病毒环状 RNA 组
PLoS Pathog. 2018 Aug 6;14(8):e1007206. doi: 10.1371/journal.ppat.1007206. eCollection 2018 Aug.
6
Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells.三氧化二砷可抑制EBV阳性淋巴瘤细胞中的EBV再激活并促进细胞死亡。
Virol J. 2017 Jun 21;14(1):121. doi: 10.1186/s12985-017-0784-7.
7
Quercetin-induced apoptosis prevents EBV infection.槲皮素诱导的细胞凋亡可预防EB病毒感染。
Oncotarget. 2015 May 20;6(14):12603-24. doi: 10.18632/oncotarget.3687.
8
Genipin as a novel chemical activator of EBV lytic cycle.京尼平作为一种新型的EB病毒裂解周期化学激活剂。
J Microbiol. 2015 Feb;53(2):155-65. doi: 10.1007/s12275-015-4672-9. Epub 2015 Jan 28.
9
Cordycepin is a novel chemical suppressor of Epstein-Barr virus replication.虫草素是一种新型的抑制爱泼斯坦-巴尔病毒复制的化学物质。
Oncoscience. 2014 Dec 18;1(12):866-881. doi: 10.18632/oncoscience.110. eCollection 2014.
10
Epigenetic regulation of EBV persistence and oncogenesis.EBV持续存在和肿瘤发生的表观遗传调控。
Semin Cancer Biol. 2014 Jun;26:22-9. doi: 10.1016/j.semcancer.2014.01.003. Epub 2014 Jan 24.

本文引用的文献

1
Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin's lymphoma.感染生发中心 B 细胞的 EBV 后发生的表观遗传学和转录变化及其与霍奇金淋巴瘤发病机制的相关性。
J Virol. 2011 Sep;85(18):9568-77. doi: 10.1128/JVI.00468-11. Epub 2011 Jul 13.
2
CTCF prevents the epigenetic drift of EBV latency promoter Qp.CTCF 防止 EBV 潜伏期启动子 Qp 的表观遗传漂移。
PLoS Pathog. 2010 Aug 12;6(8):e1001048. doi: 10.1371/journal.ppat.1001048.
3
Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.内源性表达的抗原 EBNA1 的核定位限制了巨自噬的进入和 CD4 表位展示的范围。
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2165-70. doi: 10.1073/pnas.0909448107. Epub 2010 Jan 19.
4
An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.一种在转化细胞中组成性表达且与伯基特淋巴瘤发生相关的爱泼斯坦-巴尔病毒抗凋亡蛋白:Wp/BHRF1联系。
PLoS Pathog. 2009 Mar;5(3):e1000341. doi: 10.1371/journal.ppat.1000341. Epub 2009 Mar 13.
5
Binding of CCCTC-binding factor in vivo to the region located between Rep* and the C promoter of Epstein-Barr virus is unaffected by CpG methylation and does not correlate with Cp activity.体内CCCTC结合因子与位于爱泼斯坦-巴尔病毒Rep*和C启动子之间区域的结合不受CpG甲基化影响,且与C启动子活性无关。
J Gen Virol. 2009 May;90(Pt 5):1183-1189. doi: 10.1099/vir.0.007344-0. Epub 2009 Mar 4.
6
Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL/6J mice.爱泼斯坦-巴尔病毒核抗原1不会在C57BL/6J小鼠中引发淋巴瘤。
J Virol. 2008 Apr;82(8):4180-3. doi: 10.1128/JVI.02596-07. Epub 2008 Feb 6.
7
Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.通过抑制前体mRNA加工对爱泼斯坦-巴尔病毒核抗原1表达的自我抑制
J Virol. 2008 Feb;82(4):1679-87. doi: 10.1128/JVI.02142-07. Epub 2007 Dec 12.
8
Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program.爱泼斯坦-巴尔病毒利用BSAP/Pax5来实现其生长转化程序的B细胞特异性。
J Virol. 2007 Sep;81(18):10092-100. doi: 10.1128/JVI.00358-07. Epub 2007 Jul 11.
9
Complexities associated with expression of Epstein-Barr virus (EBV) lytic origins of DNA replication.与爱泼斯坦-巴尔病毒(EBV)DNA复制裂解起源表达相关的复杂性。
Nucleic Acids Res. 2007;35(10):3391-406. doi: 10.1093/nar/gkm170. Epub 2007 May 3.
10
Translation efficiency of EBNA1 encoded by lymphocryptoviruses influences endogenous presentation of CD8+ T cell epitopes.淋巴细胞隐病毒编码的EBNA1的翻译效率影响CD8 + T细胞表位的内源性呈递。
Eur J Immunol. 2007 Feb;37(2):328-37. doi: 10.1002/eji.200636153.